| [1] |
Poller DN. Pathology of ductal carcinoma in situ of the breast: current status [J]. Eur J Surg Oncol,2001,27(5):498-503.
|
| [2] |
Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma:results of a national survey by the American College of Surgeons [J].Ann Surg,1980,192(2):139-147.
|
| [3] |
Wapnir IL, Dignam JJ, Fisher B,et al.Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS[J]. J Natl Cancer Inst,2011,103(6):478-488.
|
| [4] |
Gilleard O, Goodman A, Cooper M, et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ[J]. World J Surg Oncol,2008,6:61.
|
| [5] |
van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer [J]. Nature,2002,415(6871):530-536.
|
| [6] |
Paik S,Shak S,Tang G,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J]. N Engl J Med,2004,351(27):2817-2826.
|
| [7] |
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes [J]. J Clin Oncol, 2009,27(8):1160-1167.
|
| [8] |
Jerevall PL, Ma XJ, Li H, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial [J]. Br J Cancer,2011,104(11):1762-1769.
|
| [9] |
Dubsky P, Filipits M, Jakesz R, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ERpositive, HER2-negative early breast cancer [J]. Ann Oncol, 2013,24(3):640-647.
|
| [10] |
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status,and survival in 24,740 breast cancer cases [J]. Cancer,1989,63(1):181-187.
|
| [11] |
Skinner KA,Silberman H,Sposto R,et al. Palpable breast cancers are inherently different from nonpalpable breast cancers [J]. Ann Surg Oncol,2001,8(9):705-710.
|
| [12] |
Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer--a reappraisal [J]. Nat Rev Clin Oncol, 2010, 7(6):348-353.
|
| [13] |
Narod SA, Valentini A, Nofech-Mozes S, et al. Tumour characteristics among women with very low-risk breast cancer [J]. Breast Cancer Res Treat,2012,134(3):1241-1246.
|
| [14] |
Tavassoli FA. Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification [J]. Nat Clin Pract Oncol,2005,2(3):116-117.
|
| [15] |
Partridge AH, Elmore JG, Saslow D, et al. Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop[J]. CA Cancer J Clin,2012,62(3):203-210.
|
| [16] |
Rakovitch E, Nofech-Mozes S, Narod SA, et al. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis [J]. Breast Cancer Res Treat,2013,138(2):581-590.
|
| [17] |
Lehtimäki T,Lundin M,Linder N,et al. Long-term prognosis of breast cancer detected by mammography screening or other methods [J].Breast Cancer Res,2011,13(6):R134.
|
| [18] |
Cancello G, Maisonneuve P, Rotmensz N, et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse [J]. Ann Oncol,2013,24(3):661-668.
|
| [19] |
Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptorpositive breast cancer [J]. Clin Chem,2007,53(6):1084-1091.
|
| [20] |
Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast[J]. J Natl Cancer Inst,2013,105(10):701-710.
|
| [21] |
Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone [J]. Breast Cancer Res Treat,2015,152(2):389-398.
|
| [22] |
Alvarado M, Carter DL, Guenther JM, et al. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ:A prospective clinical utility assessment of the 12-gene DCIS scoreTM result [J]. J Surg Oncol, 2015, 111(8):935-940.
|
| [23] |
Wood WC, Alvarado M,Buchholz DJ,et al. The current clinical value of the DCIS Score [J]. Oncology (Williston Park),2014,28 Suppl 2:C2,1-8, C3.
|
| [24] |
Knopfelmacher A, Fox J, Lo Y, et al. Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score [J]. Mod Pathol,2015,28(9):1167-1173.
|
| [25] |
Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement [J]. JAMA,2013,310(8):797-798.
|
| [26] |
Kondo T, Hayashi N, Ohde S, et al. A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast [J]. J Surg Oncol, 2015, 112(5):476-480.
|